UCB SA (OTCMKTS:UCBJF – Get Free Report) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $186.09 and traded as high as $195.83. UCB shares last traded at $192.00, with a volume of 251 shares trading hands.
UCB Price Performance
The company’s 50 day moving average price is $185.98 and its 200 day moving average price is $174.38. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- What is the Euro STOXX 50 Index?
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- What is the NASDAQ Stock Exchange?
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- What Are Trending Stocks? Trending Stocks Explained
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
